Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score 13.55
- Piotroski Score 2.00
- Grade Buy
- Symbol (ATXS)
- Company Astria Therapeutics, Inc.
- Price $9.17
- Changes Percentage (-2.13%)
- Change -$0.2
- Day Low $8.61
- Day High $9.40
- Year High $16.90
Astria Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare and niche allergic, and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in preclinical development stage for the treatment of hereditary angioedema. The company was formerly known as Catabasis Pharmaceuticals, Inc. and changed its name to Astria Therapeutics, Inc. in September 2021. Astria Therapeutics, Inc. was incorporated in 2008 and is based in Boston, Massachusetts.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 03/03/2025
- Fiscal Year End N/A
- Average Stock Price Target $22.50
- High Stock Price Target $25.00
- Low Stock Price Target $20.00
- Potential Upside/Downside N/A
- Consensus Rating Sell
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$2.40
- Trailing P/E Ratio -3.69
- Forward P/E Ratio -3.69
- P/E Growth -3.69
- Net Income $-72,891,000
Income Statement
Quarterly
Annual
Latest News of ATXS
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
Companies Like Astria Therapeutics (NASDAQ:ATXS) Are In A Position To Invest In Growth
Astria Therapeutics' shareholders have seen a 126% increase in share price despite the company's cash burn. With a cash runway of 4.4 years, the company can fund its growth, though an increasing cash ...
By Yahoo! Finance | 1 month ago
